CAS NO.: 1226781-44-7
Purity :99%
CAS NO.: 1627494-13-6
Purity :99%
CAS NO.: 1260141-27-2
Purity :99%
CAS NO.: 870281-82-6
Purity :99%
CAS NO.: 1353550-13-6
Purity :99%
| Compound | 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide | ||||
|---|---|---|---|---|---|
| CAS No. | 1029712-80-8 | Catalog No. | T0009 | Brand | |
| Purity | 99% | Packing | 1g | Grade | |
| Lead Time | 14Day (s) | Origin | Loading Port | ||
| Soluble | Soluble in DMSO, not in water |
|---|---|
| Appearance & Physical State | Yellow solid powder |
| Water Solubility | Insoluble |
Capmatinib (INCB28060) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RON, as well as EGFR and HER-3. Phase 1.Inactive against RON, another member of the c-MET RTK family, as well as EGFR and HER-3 (members of the EGFR RTK family).
INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. INCB28060 inhibits human c-MET phosphorylation and c-MET-mediated signaling in cancer cells. INCB28060 inhibits c-MET-dependent cell proliferation and survival, and prevents anchorage-independent cancer cell growth and cell migration.
CAS No : 1029712-80-8
2-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1H-benzimidazole-4-carboxylic acid
CAS No : 168434-02-4
N-benzyl-2-(2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-8-methoxyquinazolin-4-amine
CAS No : 1346527-98-7
3-(4-chlorophenyl)-2-[4-(trifluoromethyl)benzyl]-1,2,4-triazino-[2,3-b]indazole
CAS No : 1360555-00-5
2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)acetic acid
CAS No : 911417-62-4
CAS No : 74-89-5
2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzoic acid
CAS No : 1029714-88-2
